Related Experiment Video
Updated: Jan 14, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Functional Characterization and Prognostic Value of PIAS Family Genes in Liver Hepatocellular Carcinoma
Ahmad Mahmood1, Zhayier Musitafa1, Shaoib Muhammad1
1Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, The First Affiliated Hospital, Xinjiang Medical University, No. 137 Liyushan South Road, 830011 Urumqi, China.
Introduction:
Liver Hepatocellular Carcinoma (LIHC) poses a significant global health burden, necessitating comprehensive molecular investigations to elucidate its pathogenesis and identify potential biomarkers and therapeutic targets.
Methods:
This study utilized Bioinformatics and detailed molecular experiments to delve into the expression profiling and epigenetic regulation of PIAS family genes in LIHC, shedding light on their diagnostic, prognostic, and therapeutic implications.
Results:
Analysis of clinical specimens revealed a pronounced up-regulation of PIAS1, PIAS2, PIAS3, and PIAS4 genes in LIHC cell lines and tissue samples compared to normal controls, emphasizing their potential as diagnostic biomarkers for LIHC. Furthermore, promoter methylation profiling unveiled significant hypomethylation of PIAS1, PIAS2, PIAS3, and PIAS4 genes in LIHC samples, implicating epigenetic dysregulation in LIHC pathogenesis. Validation using independent TCGA datasets corroborated these findings, emphasizing the robustness of PIAS family genes as diagnostic markers for LIHC. Functional analyses revealed that PIAS1 knockdown in HepG2 cells significantly impaired proliferation and colony formation, while paradoxically enhancing cell migration. These results suggest a dual role for PIAS1 in promoting tumor growth while inhibiting metastatic potential. Prognostic modeling demonstrated the collective impact of dysregulated PIAS family genes on overall survival outcomes in LIHC patients, emphasizing their clinical relevance in prognostic assessments. Furthermore, correlation analysis with immune infiltrates and drug sensitivity profiling revealed intricate interactions and therapeutic implications of PIAS family genes in LIHC.
Discussion:
The upregulation and hypomethylation of PIAS1-4 in LIHC suggest their role in tumor initiation and progression. PIAS1 knockdown impaired proliferation but increased migration, indicating a dual role in growth and metastasis. These findings align with poor patient survival linked to PIAS dysregulation. Their association with immune infiltration and drug sensitivity highlights potential for targeted therapies.
Conclusion:
This study provides valuable insights into the multifaceted roles of PIAS family genes in LIHC pathogenesis and paves the way for personalized diagnostic and therapeutic interventions.
